Accéder au contenu
Merck

Depot fluphenazine: risk/benefit ratio.

The Journal of clinical psychiatry (1984-05-01)
W M Glazer
RÉSUMÉ

The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis on controlled studies comparing depot to oral preparations. Specific gaps in our knowledge are noted and recommendations are made for future research.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Fluphenazine enantate, European Pharmacopoeia (EP) Reference Standard